Researchers find candidate recognition molecules by fusing antibody-making cells with long-lived cells, by displaying candidates on viruses or yeast and keeping those that stick, or by designing proteins on a computer. Each route gives candidates that still have to be made and tested.
Four routes to candidate binders are described in primary experiments. In 1976 Köhler and Milstein fused spleen cells from immunised mice with myeloma cells; the hybrid lines grew in culture and about 10 per cent of them showed activity against the sheep red cells used to immunise, so each line had to be tested for what it made. In 1990 McCafferty and colleagues displayed complete antibody variable domains on filamentous phage, showed that the phage bound antigen specifically, and isolated rare phage (one in a million) by affinity chromatography. In 1997 Boder and Wittrup displayed single-chain antibody fragments on yeast and used flow cytometry to compare binding kinetics, selecting a variant with a threefold lower dissociation rate. In 2023 Watson and colleagues designed binders to five targets with the RFdiffusion network, took 95 designs per target, expressed and purified them from E. coli and screened them by single-point biolayer interferometry at 10 micromolar; binding at or above half the maximal response of a positive control counted as success, the overall rate was 19 per cent, and full titrations on a subset of designs showed nanomolar affinities. Each result is a measured interaction under stated laboratory conditions. A selected, enriched or designed sequence is a candidate; the studies do not test activity in cells in a patient, absence of binding to healthy tissue, or clinical benefit.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Shares De novo designed protein binders, AI-driven drug & target discovery.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/